XML 66 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Mar. 31, 2024
Cash equivalents:    
Amortized cost $ 224,947 $ 193,706
Cash and cash equivalents 224,947 193,705
Marketable securities:    
Amortized cost 2,496 105,945
Unrealized gains 0 4
Unrealized losses (1) (1,130)
Corporate debt securities 2,495 104,819
Long-term investments:    
Amortized cost 1,108  
Unrealized gains 0  
Unrealized losses (477)  
Estimated fair value 631 46
Cash Equivalents    
Marketable securities:    
Unrealized gains   0
Unrealized losses   (1)
Money market funds    
Cash equivalents:    
Amortized cost 224,947 186,744
Cash and cash equivalents 224,947 186,744
U.S. Treasury securities    
Cash equivalents:    
Amortized cost   3,484
Cash and cash equivalents   3,484
Marketable securities:    
Amortized cost   28,341
Unrealized gains   0
Unrealized losses   (13)
Corporate debt securities   28,328
Commercial paper    
Cash equivalents:    
Amortized cost   3,478
Cash and cash equivalents   3,477
Marketable securities:    
Amortized cost   27,374
Unrealized gains   0
Unrealized losses   (23)
Corporate debt securities   27,351
Commercial paper | Cash Equivalents    
Marketable securities:    
Unrealized gains   0
Unrealized losses   (1)
Corporate debt securities    
Marketable securities:    
Amortized cost   25,509
Unrealized gains   0
Unrealized losses   (19)
Corporate debt securities   25,490
Government-related debt securities    
Marketable securities:    
Amortized cost 2,496 23,613
Unrealized gains 0 4
Unrealized losses (1) (13)
Corporate debt securities $ 2,495 23,604
Common stock in LianBio    
Marketable securities:    
Amortized cost   1,108
Unrealized gains   0
Unrealized losses   (1,062)
Corporate debt securities   $ 46